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Abstract  
Introduction: Hidradenocarcinoma is a rare aggressive tumor arising from sweat glands that may occur from 
preexisting hidradenoma or most frequently appears de novo. It is often located in the head and neck. It is 
also characterized by a high potential of local recurrence, metastasis and poor outcome. This tumor is often 
radiotherapy and chemotherapy resistant. 
Presentation of case: We report a case of a 77-year-old man with a metastatic hidradenocarcinoma to the 
bone and lymph nodes who was operated 7 years ago for an hidradenoma of the right foot. He was treated 
with capecitabine-based chemotherapy with good tolerance and obtention of partial response during 10 
months. After that, his disease progressed and he died 1 year after diagnosis. 
Conclusion: Hidradenocarcinoma is a cancer with a poor prognosis . Because of its low prevalence and high 
rate of recurrence, its treatment is still controversial. Our good result demonstrates that adjunction of 
chemotherapy in metastatic forms is effective for a better control and long overall survival. 
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Introduction   
Hidradenocarcinoma is a rare malignant skin tumor deriving from eccrine sweat glands. It is an aggressive tumor 
with a high potential of local recurrence that most metastasizes to regional lymph nodes and distant viscera. It may 
occur from preexisting hidradenoma or most frequently appears de novo [1]. Hidradenocarcinoma is often located 
on the head and neck and rarely on the extremities [2]. Liver, lung and bones are the distant sites of metastasis with 
fatal results. Because of its low prevalence and high rate of recurrence, diagnosis  remains difficult and its 
treatment controversial. Thus, until now, there is no consensual treatment for localized or metastatic disease [3-5]. 
We reported a case of a 77-year-old man with a metastatic hidradenocarcinoma of the right foot. The diagnosis, 
clinical course and management of his tumor are described and discussed based on the data in the literature. 
Case Presentation  
A 70 year-old man presented to our department with a two-year history of a painful right inguinal slow-growing 
mass. He also complained of diffuse bone pain. In his medical history, our patient was operated for a tumor of the 
right foot 7 years ago. He underwent wide excision with skin graft. Histopathological examination concluded to a 
benign tumor: hidradenoma. Otherwise, he had no family history of malignancy. Physical examination revealed a 
8x9 cm right inguinal bulky lymphadenopathy, painful, without inflammatory signs and a scar nodule of the right 
foot with keloid appearance (biopsy was not performed). Neurogical examination noted a paresis of the left arm.  
Biological tests showed an inflammatory syndrome, a hypercalcemia (2.9 mmol/l) and a   
hypergammablobulinemia. Renal and hepatic function tests were normal. 
 
 
Figure 1 The scar nodule of the right foot 
 
Figure 2  Initial computed tomography scan showing the right 
inguinal and iliac pathologic lymphadenopathy 
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Thoraco-abdomino-pelvic computed tomography noted multiple bone metastasis of the entire spine, iliac  
bones and ribs with right inguinal and iliac pathologic lymphadenopathy. We realized a biopsy of the  
inguinal mass. 
Histopathologic examination revealed a carcinomatous proliferation including basophil cells associated 
to clear cells. In immunohistochemical analysis, clear cells expressed epithelial membrane antigen (EMA), 
S100 protein, carcinoembryonic antigen (CAE) and cytokeratin 7. Basophil cells showed a positive 
staining for EMA, vimentin and cytokeratin 5/6.Tumor cells were not reactive to CDX2, CD20, calretinin, 
CD10 and cytokeratin 19. Based on these findings, diagnosis of lymph node metastasis of 
hidradenocarcinoma was established. 
After that, a chemotherapy was started and consisted on oral 5 fluorouracil chemotherapy: capecitabine 
(2500 mg/m2/day) day 1 to day 14; repeated every 21 days. Zoledronic acid was also administrated 
because of bone metastases. Our patient received also palliative radiotherapy to cervical spine with 
regression of his arm paresis. After 4 cycles of chemotherapy, clinical examination revealed an 
improvement in general condition with regression of the inguinal mass and bone pain. Computed 
tomography examination noted a partial response with stable bone lesions. Chemotherapy with 
capecitabine was continued for eight other cycles with a stable disease. But two months after he 
developed pulmonary and pleural metastasis. Second line chemotherapy was done based on intravenous 
vinorelbine  ( 25 mg/m2) weekly. After two injections, he was breathless and severely dehydrated  thus 
managed by supportive and palliative treatment, and he finally died. 
Discussion  
The management of this neoplasm is still controversial, mainly due to limited availability of literature. It 
consists mainly of surgical excision, radiation and chemotherapy [6]. For localized disease, most 
clinicians agree that wide surgical excision is the standard treatment [7]. For some authors, the Mohs 
micrographic surgery appears to be the method of choice compared to conventional wide surgical 
excision. This surgery would decrease local recurrence rate [8]. In a recent review of literature of 20 cases 
of eccrine sweat gland carcinoma treated with mohs micrographic surgery, there was no local recurrence 
[9]. Nevertheless, surgical excision is until now the standard strategy. 
The role of regional lymph nodes dissection is still controversial. Based on its high incidence of 
metastases, some authors recommend systematic lymph nodes dissection to prevent loco regional 
recurrence. Delgado et al proposed sentinel mapping and biopsy followed by lymph node dissection if the 
sentinel node was invaded . In this study, there was a high frequency of positive sentinel lymph nodes and 
metastases were detected in four patients of the six [10]. However, until now, there is no evidence of a 
benefit in survival or local control correlated with lymph node removal or sentinel lymph node mapping . 
It is partly due to the low prevalence of this tumor. Further studies are necessary to determine the optimal 
strategy [1]. 
The role of radiotherapy in clear cell hidradenocarcinoma has changed. Before, this tumor was 
considered radio-resistant. Recent reports have shown that post-operative radiotherapy improves local 
control and it should be performed when predictive factors of recurrence are present: positive margins, 
vascular, lymphatic and perineural invasion, poorly differentiated tumors, lymph node involvement and 
extra capsular spread [11]. The dose of radiotherapy is not consensual. In the study of Harari et al, sweat 
gland tumors with positive margins were treated by external beam radiotherapy: 70 Gy in the primary 
surgical bed and 50 Gy in the lymphatic chains with complete remission consisting of 27-35 months 
disease-free period [12]. 
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The role of chemotherapy remains also unclear. No benefit of adjuvant chemotherapy has been shown 
until now. However, in metastatic hidradenocarcinoma, some case reports described a benefit of various 
chemotherapy agents. Jouary at al reported the benefit of capecitabine in a 60 year-old-woman with 
metastatic hidradenocarcinoma. Treatment resulted in more than 50% of clinical remission with 
acceptable clinical and biological tolerance [13]. In our case, the patient received capecitabine with partial 
clinical response after 4 cycles followed by a stability after 8 other cycles but the disease progressed after 
that. Overall survival was 12 months.  
In the literature, other chemotherapy regimens has been reported using intra-venous 5 fluorouracil, 
doxorubicin and platin regimen leading to better disease control [14]. In another case report, a 35 
year-old-woman with metastatic hidradenocarcinoma (lung metastases) was treated with navelbine and 
cisplatin with obtention of a stable disease after 6 cycles [15]. 
Target therapies have also been tested in clear cell hidradenocarcinoma (CCH). Based on 
histomorphologic overlap between sweat gland origin and breast adenocarcinomas, some investigators 
studied the expression of oestrogen receptors and HER 2 neu protein in CCH to test the efficacy of 
tamoxifen and trastuzumab. In the study of Nash et al, the investigators reported the benefit of adjuvant 
trastuzumab in patients whose tumors over expressed HER2 neu. A 44-year-old-man was treated with 
wide local excision, lymph node dissection, adjuvant radiotherapy and chemotherapy and trastuzumab 
because of HER 2 neu gene amplification. He performed a complete response. 
In analogy to breast carcinoma and based on findings showing the benefit of trastuzumab in metastatic  
breast cancer, authors suggest the uses of trastuzumab in metastatic adnexal carcinomas [16]. 
Other investigators evaluated the efficacy of tamoxifen in eccrine adenocarcinoma [16]. Kasi at al 
reported two cases of metastatic sweat gland carcinoma with expression of oestradiol receptors , treated 
with tamoxifen. Hormonal therapy achieved a prolonged partial response in these patients. Shroder at al 
reported also a success of adjuvant tamoxifen therapy after a local recurrence treated by surgery in a 
64-year-old-woman with a sweat gland adenocarcinoma of the scalp [17]. 
Conclusion 
Hidradenocarcinoma remains a cancer with a poor prognosis. Our good result demonstrates that despite 
its chemotherapy resistance, adjunction of chemotherapy in metastatic forms is effective for a better 
control and long overall survival. 
Consent 
We confirm that family members of the patient have given their informed consents for the case report to 
be published. 
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